CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Successful treatment of pulmonary lymphomatoid granulomatosis with PD-1 inhibitor-based regimen: A Case Report and Literature Review
Provisionally accepted
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pulmonary lymphomatoid granulomatosis (PLG) is a rare and aggressively progressive tumor characterized by atypical clinical manifestations and pathological features. This condition is notably susceptible to misdiagnosis and underdiagnosis. The absence of standardized treatment regimens has led to various recommendations in the literature, predominantly favoring, Rituximab-based regimens. However, the prognosis for these patients has been consistently poor, with a median survival time of only 14 months. Recently, we encountered a case of PLG exhibiting PD-1, PD-L1 and P53 expression. We administered a programmed cell death-1 (PD-1) inhibitor-based regimen. Remarkably, the patient had an overall survival (OS) of 52 months as of the most recent follow-up, without disease progression. This case stands as a notable observation, particularly, because the utilization of a PD-1 inhibitor-based regimen has not been previously reported for PLG treatment. We hope this case could contribute significantly to enhancing physicians' comprehension of PLG and provide new potential treatment strategy.
Keywords: PD-1 inhibitor, Pulmonary lymphomatoid granulomatosis, Rituximab-based regimens, survival time, treatment strategy
Received: 07 Sep 2025; Accepted: 15 Dec 2025.
Copyright: © 2025 Liu, Gao, Wu, JIa, Cao, Yu, Zhang, Zhao and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jie Ma
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.